Quantcast
Thursday, April 25, 2024

Big Pharma Attacks Ivermectin While Pursuing More Expensive Imitations

'We do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information...'

Big pharmaceutical corporations in America have continued to attack ivermectin—a drug promoted by some conservatives to treat COVID-19.

Meanwhile, companies including Merck may be developing more costly imitations of the drug even as they seek to discredit it, Uncanceled News reported.

In light of increasing concerns surrounding Big Pharma’s rushed vaccines, many Americans have turned to ivermectin for treatment.

The drug is sometimes used to treat parasitic worm infections in humans and livestock, although it has long been used for other medicinal purposes.

Nonetheless, hysterical leftist media and government agencies have attacked the use of the cheap alternative, instead electing to force millions of Americans to get the unstudied and unproven COVID vaccines in the sacred name of science.

The partisan Food and Drug Administration, for example, has warned Americans against using ivermectin, dismissing it as “horse” and “cow” medicine that coronavirus patients should not use.

Nonetheless, Merck, a major producer of ivermectin, announced last week that it had begun production of its new oral antiviral pill, molnupiravir.

Despite its hand in the production of ivermectin, the Merck sided with the media and the FDA in the attack on the long-used drug.

The company released a statement, saying,  “We do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information.”

Of course, the new drug will cost substantially more, resulting in substantial profits for Merck and other major international pharmaceutical corporations.

According to the report, the FDA will soon give Merck’s molnupiravir emergency use authorization.

Copyright 2024. No part of this site may be reproduced in whole or in part in any manner other than RSS without the permission of the copyright owner. Distribution via RSS is subject to our RSS Terms of Service and is strictly enforced. To inquire about licensing our content, use the contact form at https://headlineusa.com/advertising.
- Advertisement -

TRENDING NOW

TRENDING NOW